[Essential arterial hypertension. A therapeutic proposal].
The therapeutical efficacy and the tolerance of a long-range treatment with Aldatense were evaluated in 77 patients with essential hypertension. A standard treatment period of 120 days was set and the posology personalized (Aldatense 1 or 2 tablets/day) according to the therapeutical response observed at the controls carried out 1 week, 30, 60, 90 and 120 days from beginning treatment. The data obtained show that Aldatense exerts a strong anti-hypertension action; its effect is gradual and progressive and becomes chronically stable. The therapeutical index of the product proved good as the incidence of side effects was very low. In particular Aldatense did not interfere with blood potassium levels, glucides and purines metabolism and renal function.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001581:Benzothiadiazines; D002191:Canrenoic Acid / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007605:Juvenile Hormones / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D012110:Reserpine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D004338:Drug Combinations; D007605:Juvenile Hormones; D011245:Pregnadienes; D049993:Sodium Chloride Symporter Inhibitors; D013449:Sulfonamides; D002191:Canrenoic Acid; D012110:Reserpine; C006480:althiazide
Ipertensione arteriosa essenziale. Una proposta terapeutica.